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ABSTRACT 
Emerging contaminants refers to a group of micropollutants found in the 
environment at trace concentrations (µg/L or ng/L). These contaminants are not currently 
covered by existing water-quality regulations, although they could represent a threat to the 
ecosystem and for human health and safety. Pharmaceuticals are indispensable to ensure 
human quality of life; however, they are a representative group of emerging contaminants. 
In fact, a great portion of pharmaceuticals is normally excreted from human body in parental 
form or as metabolites, which could be loaded into the aquatic environment when the 
removal process in the wastewater treatment plant (WWTP) is not efficient.  
Microbial communities have the ability to metabolize a wide variety of contaminants 
and are known to be able to colonize contaminated environments. Towards this, the present 
work aimed to develop bioremediation techniques that can stimulate the intrinsic capacity 
of autochthonous microbial communities to degrade pharmaceuticals in an urban estuary 
and associated WWTP. As representatives of extensively used pharmaceuticals, this study 
was focused on an antidepressant drug, Paroxetine, and on a lipid regulator, Bezafibrate. 
Two experiments were carried out using microorganisms originated from different sources: 
(i) sediments from the Douro estuary and (ii) activated sludge from a local WWTP. 
The first experiment consisted in enrichment cultures of mixed consortia of 
autochthonous microorganisms with capacity to grow in the presence of the selected 
pharmaceuticals, obtained from samples collected at the two sources. The enrichment was 
carried out in batch mode, under different incubation conditions (agitation vs. static), by 
exposing the cultures to the different pharmaceuticals (1 mg/L) in co-metabolism with 
acetate (500 mg/L). The biodegradation potential was monitored at the end of each feeding 
cycle (2 weeks) by analyzing both pharmaceuticals in solution (by High Performance Liquid 
Chromatography). In the case of Paroxetine, fluoride ion release was also followed as an 
indicator of defluorination of the molecule (through ion selective analysis). Microbial 
biomass growth was estimated by optical density of cultures (by spectrophotometry at 600 
nm). Microbial community was characterized by Automated Ribosomal Intergenic Spacer 
Analysis at the end of first (2 weeks) and last (14 weeks) feeding cycle. Important changes 
occurred in the microbial community structure, influenced by time of experiment, incubation 
conditions and pharmaceuticals presence. Indeed, incubation conditions affected not only 
the bacterial community structure, but also the efficiency of pharmaceuticals removal that 
was initially lower under agitation than under static conditions. At the end of the experiment, 
results showed high removal of the pharmaceuticals from solution (>97%) due to biotic 
iii 
 
processes. However, in case of paroxetine, removal was also due to adsorption and abiotic 
processes, however, defluorination only occur in the presence of microorganisms.  
The second study aimed to evaluate the capacity of isolated strains derived from the 
enrichment cultures obtained in the first experiment, re-united in new consortia to degrade 
the selected pharmaceutical to which they were previously exposed. Thus, five sets of 
microcosms were assembled: two consortia derived from Paroxetine enrichment under 
static conditions, of which one was obtained from estuarine sediment and the other from 
activated sludge from WWTP, and three consortia derived from Bezafibrate enrichment, two 
under static conditions, of which one was obtained from estuarine sediment and the other 
from activated sludge, and the last obtained from activated sludge microcosms under 
agitation conditions. Results showed that despite different acclimation times, high removal 
efficiency of pharmaceuticals (>97%) was obtained in three of the five studied consortia. 
Moreover, consortia from estuarine sediment was more efficient in removing both studied 
pharmaceuticals. In the case of paroxetine, microorganisms present in consortia were able 
to promote fluoride anion release. Complementary analysis in terms of identification of the 
isolated strains will allow to understand which are the microorganisms present in consortia, 
responsible for bezafibrate and paroxetine degradation. 
This work emphasizes the potential of autochthonous microorganisms from 
estuarine environment and associated WWTP, for application in bioremediation techniques, 
namely autochthonous bioaugmentation for pharmaceuticals removal. 
 
Keywords: Bioremediation; Bezafibrate; Paroxetine; microbial community; 
autochthonous microorganisms  
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RESUMO 
Contaminantes emergentes são um grupo de micropoluentes encontrados no 
ambiente em concentrações vestigiais (µg/L or ng/L). Estes contaminantes não se 
encontram atualmente sob regulação da qualidade da água, contudo podem representar 
uma ameaça para o ecossistema, saúde e segurança humana. Os fármacos são 
indispensáveis para assegurar qualidade de vida ao Homem; contudo, são um grupo 
representativo de contaminantes emergentes. De facto, uma grande porção dos fármacos 
é excretada do corpo humano na forma do composto parental ou como metabolito, 
podendo atingir o meio aquático quando a sua remoção nas estações de tratamento de 
água residuais (ETAR) não é eficiente. 
As comunidades microbianas têm a capacidade de metabolizar uma grande 
variedade de contaminantes, sendo reconhecidas pela sua capacidade de habitar em 
ambientes contaminados. O presente trabalho tem como objetivo desenvolver técnicas de 
biorremediação que consigam estimular a capacidade intrinseca de comunidades 
microbianas autóctones para degradar compostos farmacêuticos em estuário urbano e 
ETAR associada. Como representantes de fármacos extensamente consumidos, este 
estudo foca-se num fármaco antidepressivo, Paroxetina e em um regulador lipidico, 
Bezafibrato. Duas experiências foram desenvolvidas, utilizando microrganismos com 
origem em duas fontes diferentes: (i) sedimentos do estuário do Douro e (ii) lamas ativadas 
de uma ETAR local. 
A primeira experiência consistiu no enriquecimento de culturas do consórcio de 
microrganismos autóctones com capacidade de crescer na presença dos fármacos 
selecionados, obtidos a patir de amostras recolhidas nas duas fontes. O enriquecimento 
foi desenvolvido sob diferentes condições de incubação (agitação vs. estático), com a 
exposição das culturas aos diferentes fármacos (1 mg/L) em co-metabolismo com acetato 
(500 mg/L). O potencial de biodegradação foi monitorizado  no fim de cada ciclo (2 
semanas) através da análise da presença do fármaco em solução (por Cromatografia 
Liquida de Alto Desempenho). No caso da Paroxetina, a libertação do ião fluoreto também 
foi seguida como um indicador da defluorinação da molécula (através de análise seletiva 
do ião). O crescimento da biomassa microbiana  foi estimada por medição da densidade 
ótica das culturas (por espectrofotometria a 600 nm). A comunidade microbiana foi 
caracterizada por Análise de Espaçador Intergênico Ribossômico Automatizado  no final 
do primeiro (2 semanas) e último (14 semanas) ciclos. Alterações importantes ocorreram 
a nível da estutura da comunidade, influenciadas pelo tempo da experiência, condições de 
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incubação e presença dos fármacos. De facto, as condições de incubação afetaram não 
só  estrutura da comunidade bacteriana, como também a eficiência de remoção dos 
fármacos que por sua vez foi mais baixa em condições de agitação do que em condições 
estáticas. No final da experiência, os resultados demonstraram elevadas eficiências de 
remoção dos fármacos de solução (>97%) devido a processos bióticos. Contudo, no caso 
da paroxetina, a remoção também foi devia a processos abióticos e de adsorção, contudo, 
a defluorinação apenas foi verificada na presença de microrganismos. 
O segundo estudo pretendeu avaliar a capacidade de estirpes de bactérias isoladas 
derivadas das culturas de enriquecimento obtidas na primeira experiência, reunidas num 
novo consorcio, para degradar os fármacos selecionados, aos quais tinham sido 
previamente expostas. Assim, cinco consórcios foram obtidos: dois derivaram do 
enriquecimento com Paroxetina sob condições estáticas, sendo que um deles teve origem 
nos sedimentos estuarinos e o outro nas lamas ativadas de ETAR. Os outros três 
consórcios derivaram do enriquecimento com Bezafibrato, dos quais dois foram obtidos do 
enriquecimento sob condições estáticas, um com origem nos sedimentos estuarinos e o 
outro nas lamas ativadas, e o terceiro foi obtido de microcosmos de lamas ativadas sob 
condições de agitação. Os resultados demonstraram, que apesar dos diferentes tempos 
de aclimatização, elevadas eficiências de remoção (>97%) foram obtidas em três dos cinco 
consórcios estudados. Além disso, os consórcios obtidos a partir de sedimentos estuarinos 
demonstraram ser mais eficientes na remoção dos dois fármacos em estudo. No caso da 
Paroxetina, os microrganismos presentes no consórcio foram capazes de promover a 
libertação do anião de fluoreto. Análises complementares em termos de identificação das 
estirpes isoladas vão permitir perceber quais os microrganismos presentes em cada 
consórcio responsáveis pela degradação de Paroxetina e Bezafibrato. 
Este trabalho emfatiza o potecial de microrganismos autóctones presentes em 
ambiente estuarino e ETAR associada para a aplicação em tecnicas de biorremediação, 
nomeadamente bioaumento autóctone para remoção de fármacos. 
Palavras-Chave: Biorremediação; Bezafibrato; Paroxetina; comunidade 
microbiana; microrganismos autóctones 
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1. INTRODUCTION 
1.1. BACKGROUND 
Until the beginning of the last decade of 20th century the concern about 
environmental pollution was caused by the presence of persistent organic pollutants and 
metals, mostly produced by the industrialization that occurred until that period (Petrović et 
al., 2003). However, the rapid advances of sensitive analytical techniques allowed to 
analyze more complex environmental matrix, targeting the attention to previously 
undetected substances in aquatic environment (Richardson and Bowron, 1985, Farré et al., 
2008). These substances were denominated as “emerging contaminants”, being their 
concentration in the environment not covered by water-quality regulations, potentiating their 
widespread and potential threats to ecosystems. This group includes a variety of products 
used daily, including pharmaceuticals, personal care products, steroids and hormones, 
drugs of abuse, surfactants, flame retardants, industrial additives and agents, and gasoline 
additives, without discarding their transformation products (Petrović et al., 2003, Farré et 
al., 2008). Despite the fact that the environmental concentrations of these compounds are 
not regulated, their constant introduction in the environment can cause harm to living 
organisms, irrespective of their recalcitrance (Petrović et al., 2003). 
Pharmaceuticals are a large group of organic chemicals, included in emerging 
contaminants, extensively used in human and veterinary medicine. For that, they raise a 
special concern regarding their environmental presence since they are created to be 
biologically active, having a specific mode of action (Fent et al., 2006). According to their 
purpose, veterinary or human medicine, pharmaceuticals can be transported and distributed 
in the environment by different routes, depending on their physicochemical properties (e.g. 
water solubility and polarity) (Fig. 1) (Halling-Sørensen et al., 1998, Cunningham et al., 
2004, Farré et al., 2008). Depending on their application (e.g. fish farms, therapeutic 
treatment), veterinary pharmaceuticals can enter the environment through different routes. 
On the other hand, human pharmaceuticals, after being metabolized, are expelled in the 
parental form and as metabolites in urine and feces, entering in wastewater treatment plants 
(WWTPs) (Richardson and Bowron, 1985, Halling-Sørensen et al., 1998, Farré et al., 2008). 
In WWTP some of these compounds can be removed by biodegradation or retained in 
sludge. Still, some compounds can be hydrophilic, thus remaining in soluble phase, and 
can be considered recalcitrant substances (Richardson and Bowron, 1985). Since 
conventional WWTP were initially not designed to remove emerging contaminants, these 
facilities are now considered one of the major sources of human pharmaceuticals to surface 
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waters, affecting aquatic organisms if still biologically active (Richardson and Bowron, 1985, 
Halling-Sørensen et al., 1998, Petrović et al., 2003, Fent et al., 2006, Farré et al., 2008). 
Furthermore, transport of pharmaceuticals to surface and ground water can occur when 
sludge from WWTP and manure from feedstock industry are applied on fields as fertilizers, 
due to their abundant content in organic matter. Indeed, potentially adsorbed 
pharmaceuticals can affect soil and water organisms, through leaching or runoff of 
contaminated soil (Halling-Sørensen et al., 1998, Fent et al., 2006, Farré et al., 2008). 
 
 
In recent years, a great concern about antibiotics emerged among the scientific 
community, due to an increase in resistant bacteria in the environment. However, other 
classes of compounds should not be ignored, especially polar compounds, as acid 
pharmaceuticals, because they have a natural capacity to resist WWTP treatments, arising 
as a potential risk in drinking water supply (Petrović et al., 2003). 
Pharmaceuticals 
Veterinary 
Pharmaceuticals 
Human 
Pharmaceuticals 
Field WWTP 
Treated wastewater Sludge 
Aquatic 
environment 
Effects in aquatic and soil organisms 
Groundwater 
Figure 1 – Pharmaceuticals fate in the environment [Adapted from: Halling-Sørensen et al. 
(1998)] 
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The present research is focused on pharmaceutical compounds, which are 
representatives of two extensively consumed therapeutic classes: a lipid regulator, 
Bezafibrate (Bzf), and an antidepressant, Paroxetine (Prx). 
1.2. PHARMACEUTICAL COMPOUNDS 
1.2.1. Bezafibrate 
The increase in population with obesity and increased diagnosis and treatment 
promoted an exponential prescription and consumption of cholesterol-lowering 
pharmaceuticals (OECD, 2013). Indeed, in some countries that belong to the Organisation 
for Economic Co-operation and Development (OECD), the consumption of these classes of 
pharmaceuticals more than tripled from 2000 to 2011. In Portugal, the consumption of 
cholesterol-lowering pharmaceuticals increased from 19 defined daily doses (DDD) per 
1000 inhabitants per day in 2000, to 88 DDD per 1000 inhabitants per day in 2011 (OECD, 
2013). 
Bzf is a commonly acidic pharmaceutical prescribed to treat hyperlipidemia, 
hypercholesterolemia and mixed hyperlipidemia (Tang et al., 2014), holding a chlorine atom 
in its molecule, linked to a benzene ring. According to its physicochemical properties (Table 
1), the acidity profile of Bzf is determinant for its environmental fate, since at environmental 
conditions anionic form of Bzf is favored (Luo et al., 2014).  
 
Table 1 - Relevant physicochemical properties of Bezafibrate 
 
Molecular Structure 
 
Molecular Formula C19H20ClNO4 PubChem 
Molecular Weight 361.8194 PubChem 
Acid Dissociation Constant (pKa) 3.6 Tang et al. (2014) 
Partition coefficient (Log Kow) 4.25 Petrie et al. (2013) 
Organic Carbon normalized sorption coefficient 
(Log KD) 0.033 
Ternes et al. 
(2007) 
Water solubility (25 ºC) (mg/L) 7.9 Petrie et al. (2013) 
Henry’s Law Constant (atm-m3/mol) 2.12x10-15 Petrie et al. (2013) 
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Although the partition coefficient suggests that adsorption to sediments or sludge 
would be likely to occur (Log Kow>4), the more accurate prediction takes in consideration 
Kow and pKa. In this way, the balance between these chemical characteristics indicates that 
Bzf can be removed by adsorption or remain in water phase, depending on environmental 
physicochemical parameters (Luo et al., 2014). 
Bzf is considered to have a relatively high rate of excretion from human body (40-
69%), commonly being detected in influents of WWTP. In here, its removal is not always 
well-stablished. Lara-Martín et al. (2014) reported that Bzf present in the influent of a WWTP 
was completely removed during treatment, while Jelic et al. (2011) stated that only 14% of 
Bzf was removed during treatment at WWTP. On the other hand, Lindqvist et al. (2005) has 
reported removal efficiencies in a range of 15-100%. Thus, Bzf removal at WWTP was 
considered as a “Moderate Removal” (Luo et al., 2014). 
Several studies reported the presence of Bzf in WWTP, through influents (Lindqvist 
et al., 2005, Luo et al., 2014, Pereira et al., 2015) (Table 2). Radjenović et al. (2009) 
reported a concentration rang of 1900–29800 ng/L in effluent of primary treatment, while 
Lindqvist et al. (2005) reported the presence of Bzf in discharge point of WWTP (4-24 ng/L) 
and downstream from the discharge point (3 ng/L). Despite being sporadically detected in 
sediments or suspended solids, main concern arises from the presence of Bzf on discharge 
point of WWTP and its presence on surface water. Results in published literature suggest 
that inconsistent removal rates lead to the presence of Bzf in surface waters in European 
countries at a concentration range of 25-3100 ng/L (WHO, 2012). In Portugal, Gonçalves 
et al. (2013) reported the presence of Bzf in surface water, at a concentration range of 256-
770 ng/L. 
 
Table 2 - Occurrence of Bezafibrate in different environmental compartments 
 
 Concentration (ng/L) Reference 
 
  
WWTP influent 3500 Luo et al. (2014) 35.6-6000 Pereira et al. (2015) 
WWTP effluent 
5.8-324  Silva et al. (2011) 
4-24 Lindqvist et al. (2005) 
40-24000 Pereira et al. (2015) 
Superficial Water 
2.01-25.5 Silva et al. (2011) 
3-4  Lindqvist et al. (2005) 
256-770 Gonçalves et al. (2013) 
 Concentration (ng/g) 
 
Suspended solids 1.17-203 Silva et al. (2011) 
Sediments 0.5 Silva et al. (2011) 
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Bzf was classified as a high priority emerging contaminant, since it can have a 
significant impact in environmental health (GWRC, 2009). Toxicity effects indicated that this 
pharmaceutical compound can be harmful to aquatic life. Studies of ecotoxicology 
developed by Blaise et al. (2008) demonstrated that species from decomposers to 
secondary consumers can be negatively affected by the presence of Bzf in aquatic 
environment, either in acute or chronic exposition. Vibrio fischeri can suffer toxic effects at 
a concentration >15.6 mg/L, at acute tests, having its luminescence inhibited, while 
Pseudokirchneriella subcapitata can have growth inhibited at concentration >31.3 mg/L, at 
chronic toxicity tests. Micro-invertebrates Hydra attenuata and Thamnoocephalus platyurus 
were also demonstrated to be sensitive to Bzf presence at concentrations of 5.3 and >62.5 
mg/L, respectively. And for T. platyurus mortality was observed at the reported 
concentration (62.5 mg/L). Acute citotoxicity test also demonstrated that primary 
hepatocytes of Oncorhynchus mykiss were damaged at concentration >362 mg/L.  
Nevertheless, one should be aware that these concentrations are much higher than 
those normally found in the environment. 
1.2.1. Paroxetine 
Antidepressant pharmaceuticals had their consumption increased in most OECD 
countries. This can be related with the earlier diagnostic and consequently, the intensity 
and duration of treatment. Despite that, the milder forms of depression, as anxiety, can 
extend the treatment time, increasing the consumption over time. In Portugal, a rise of 20% 
in consumption was verified between 2007 and 2011 (OECD, 2013). Prx is an 
antidepressant pharmaceutical, that belongs to selective serotonin reuptake inhibitors 
(SSRIs), being one of the most prescribed drug to treat anxiety and depression (Brown et 
al., 2015). Table 3 represents a brief resume of some important characteristics of Prx. The 
high value of Log Kow may suggest that Prx can adsorb to sediments and organic matter. In 
fact, in environmental conditions, Prx is found commonly in the cationic form, which can 
potentiate the formation of a complex with sediments or organic carbon (OC) (negatively 
charged) (Kwon and Armbrust, 2008, Brown et al., 2015, Semblante et al., 2015). 
Furthermore, its distribution coefficient (KD) indicates that Prx can be either extremely 
adsorbed or just slightly, especially with pH increasing (Brown et al., 2015). Prx has not 
raised a high attention regarding its toxic effects because it is mostly excreted as 
metabolites either in feces and urine, and only 3% are expelled in parental form 
(Cunningham et al., 2004).  
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Table 3 - Relevant physicochemical properties of Paroxetine 
 
Several studies have reported Prx presence in effluents, being also detected in 
surface water (Table 4). Concentration of 90 ng/L of Prx in surface water (Wu et al., 2009) 
and 150-386 ng/L at WWTP effluents (Collado et al., 2014) have been reported. However, 
due to its physicochemical behavior, it has a great tendency to be retained in organic matter 
(Brown et al., 2015). Indeed, Wu et al. (2009) has reported that Prx was present in biosolids 
from a local WWTP in a concentration of 87 ng/g. 
Table 4 - Occurrence of Paroxetine in different environmental compartments 
 
Daphnids are sensible to Prx at 50 µg/L and 490 µg/L, in chronic and acute toxicity 
tests (Brown et al., 2015). Toxic effects of Prx on Mytilus edulis were also studied. Prx lead 
to loss in cell viability at 15 mg/L and to DNA strand breaks in hematocytes at concentration 
Molecular Structure 
 
Molecular Formula C19H20FNO3 PubChem 
Molecular Weight 329.365403 g/mol PubChem  
Acid Dissociation Constant (pKa) 9.6 Cunningham et al. (2004) 
Partition coefficient (Log Kow) 3.6 PubChem 
Organic Carbon normalized sorption 
coefficient (KD) 131-5067 Brown et al. (2015) 
Water solubility (25 ºC) (mg/L) 6804 Cunningham et al. (2004) 
Henry’s Law Constant (atm-m3/mol) <10-8 to 10-12 Cunningham et al. (2004) 
 Concentration (ng/L) Reference 
WWTP influent 
270 Lara-Martín et al. (2014) 
16 Verlicchi et al. (2012) 
9.1-9.7 Schlüsener et al. (2015) 
WWTP effluent 
150-386 Collado et al. (2014) 
16 Verlicchi et al. (2012) 
2.3-2.4 Schlüsener et al. (2015) 
Superficial Water 90 Wu et al. (2009) 
 Concentration (ng/g) 
 
Biosolids 87 Wu et al. (2009) 
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of 1.5 µg/L (Lacaze et al., 2015). In this study, genotoxic impact of Prx was associated to 
its cytotoxic effect. Furthermore, Prx was considered one of the most toxic compounds of 
the study. Also, Prx was detected in fish tissue (Gelsleichter and Szabo, 2013). Thus, Prx 
can have an important impact in the ecosystem, because it can be present in the 
environment, causing effects in organisms and bioaccumulating. 
1.3. MICROBIAL COMMUNITIES AND BIOREMEDIATION 
Natural ecosystems functioning is dependent on microorganism’s activity, since they 
are primary producers, decompose organic matter, participate in nutrient cycles and are 
considered natural attenuators (Altieri, 1999, Stenuit et al., 2008). Microorganisms have a 
key role in soil and water purification processes, although the presence of a diverse and 
abundant microbial community is essential to promote an effective response to the different 
contamination agents (Oladele, 1999, Allison and Martiny, 2008). Several laboratory studies 
(Carvalho et al., 2006, Yu et al., 2006, Zhu et al., 2007, Barra Caracciolo et al., 2013, Ribeiro 
et al., 2013, Abed et al., 2014, Dey et al., 2016, Sheu et al., 2016, Wang et al., 2016) 
reported the efficient degradation of different pollutants by microbial communities or single 
bacterial strains, obtained from known contaminated sites.  
Bioremediation is a cost-effective tool that uses microbial consortia or bacterial 
strains to remove pollutants from the environment and remediate contaminated 
environments. It emerged in environmental biotechnology field and has been increasingly 
studied and applied in real situations (Stenuit et al., 2008, Juwarkar et al., 2010). 
Bioremediation techniques include natural attenuation, biostimulation and bioaugmentation. 
While natural attenuation corresponds to the natural remediation capacity of a microbial 
community present in a contaminated site to control the spread of contamination, 
biostimulation requires the addition of nutrients or electron acceptors to stimulate the 
intrinsic degradation capacity of bacteria. Bioaugmentation is characterized by the 
inoculation of contaminated sites with strains or microbial consortia with biodegrading 
capacities in sites where natural attenuation does not exist, where microorganisms do not 
have degradative capacity, or is too slow (Stenuit et al., 2008, Hosokawa et al., 2009, 
Juwarkar et al., 2010). This technique has three different approaches: i) application of 
indigenous microorganisms, ii) application of exogenous microorganisms and iii) application 
of genetically modified microorganisms (Hosokawa et al., 2009, Juwarkar et al., 2010). 
Application of genetically modified microorganisms can cause negative impacts on the 
environment, and so its application involves strict rules. Moreover, bioaugmentation 
technique involving the application of exogenous microorganisms can present 
disadvantages, since effects on natural microbial community and environment are 
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unknown, and exogenous microorganisms are most of the times incapable to compete with 
indigenous microorganisms (Hosokawa et al., 2009). The use of indigenous 
microorganisms - autochthonous bioaugmentation - can be more efficiency, since the use 
of microorganisms from the specific contaminated sites, can decrease the period of 
acclimatization and adaption to the autochthonous conditions.  
However, bioremediation techniques require an extensive knowledge on 
physicochemical properties of the pollutant, as well as on the microbial community 
regarding its structure, phenotypic potential, function and environmental interactions 
(Stenuit et al., 2008). Fingerprinting approaches, as Automated Ribosomal Intergenic 
Spacer Analysis (ARISA), is a cost-effective and rapid method to study complex 
communities in a variety of ecosystems or controlled experiments, though fingerprint does 
not inform about taxonomic profile. However, consistencies between microbial structures 
generated from ARISA fingerprint and more in-depth methods, as 454-pyrosequencing, 
were reported (Stenuit et al., 2008, van Dorst et al., 2014). ARISA targets the intergenic 
transcribed spacer (ITS), a region with great taxonomic resolution that allows verifying 
genome diversification and evolutionary relationship (Ettoumi et al., 2013).  
To better understand the response of a microbial community to a specific pollutant, 
it is necessary to study their interactions. Laboratory microcosms are recognized as 
ecosystem models, since they contain natural biotic communities under controlled 
environmental conditions (e.g. temperature and light). Confined environment of microcosms 
allows to stablish a causal relationship between the pollutant and its effects on the studied 
community (Barra Caracciolo et al., 2013), that would not be possible in natural ecosystem 
due to the interference of non-controlled environmental factors.  
1.4. CONTAMINATED SITES 
In literature, the relation between environmental contamination and anthropogenic 
activity is well-stablished. In fact, the increase of hazardous waste sites around the world is 
proportional to increase of population. Despite some of the pollutants being natural 
compounds (e.g. fossil fuels, metals), human activity has a key role in the contamination of 
the environment by these compounds, as well as by emerging contaminants.  
As previously reported, WWTPs are described as pharmaceuticals contamination 
source, since these compounds have a tendency to accumulate in sludge or be release into 
the surface water (Farré et al., 2008). When in surface water, pharmaceuticals can be 
distributed in the ecosystem, reaching estuarine ecosystems. Thus, bacterial communities 
present in both systems can interact with these substances. 
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Knowing that autochthonous bacterial communities with natural remediation 
capacities can be present in contaminated sites, the collection of these microorganisms can 
be useful for the development of bioremediation techniques, such as autochthonous 
bioaugmentation, with the application of specific strains or microbial consortia in 
contaminated sites. 
1.4.1. Douro estuary 
The Douro River is an international river, flowing 930 Km since its source in Sierra 
de Urbión, Spain, until the river mouth in Oporto city, Portugal. Aside from being the third 
longest river in the Iberian Peninsula, its watershed is the largest in the Iberian Peninsula 
(98000 km2). Over its flow, Douro River receives water from several natural effluents both 
in Spain and in Portugal. Douro river estuary is considered an urban estuary since 
approximately 550 000 inhabitants occupy both banks. Douro estuary receives effluents 
from eight WWTPs, either directly or indirectly, in which two of them discharge to the 
estuary. These two WWTPs treats wastewater residues from an equivalent of 370 000 
inhabitants (Madureira et al., 2010).  
In the last decades, Douro River estuary has been indicated as a highly 
contaminated environment (Fig. 2) due to the high anthropogenic pressure that it 
undergoes. Several studies reported the presence of metals (Mucha et al., 2003, Mucha et 
al., 2004, Gravato et al., 2010), endocrine disruptors (Ribeiro et al., 2009, Rocha et al., 
2012), polycyclic aromatic hydrocarbon (Gravato et al., 2010), pesticides (Waszak et al., 
2014) and pharmaceuticals (Madureira et al., 2010) in Douro estuary. 
 
 Metals  Polycyclic Aromatic Hydrocarbon  Pharmaceuticals 
 Pesticides  Endocrine Disruptors 
Figure 2 - Reported contaminants detected at Douro estuary [Adapted from: Mucha et 
al., 2003, Mucha et al., 2004, Ribeiro et al., 2009, Gravato et al., 2010, Madureira et al., 
2010, Rocha et al., 2012, Waszak et al., 2014)] 
22 
 
1.5. OBJECTIVES 
The present work aimed to explore the potential of autochthonous microorganisms, 
from Douro estuary sediments and from activated sludge of a WWTP discharging into the 
estuary, for bioremediation of pharmaceuticals. As representatives of extensively used 
pharmaceuticals, an antidepressant drug (Prx) and a lipid regulator (Bzf) were chosen. Two 
experiments were separately conducted to understand the biodegradation capacity of 
microbial communities from the two origins.  
The first experiment was carried out in microcosms inoculated with estuarine 
sediment or activated sludge, doped with one of the selected pharmaceutical compounds 
(Bzf or Prx), in batch mode, with different agitation conditions. This experiment aimed to 
evaluate changes in microbial community structure caused by the presence of the 
pharmaceutical compound and the effects of incubation conditions and time. It also aimed 
to understand the involvement of these microorganisms in pharmaceuticals 
removal/degradation from the medium.  
The second study aimed to evaluate the capacity of isolated strains derived from the 
enrichment culture in the first experiment, re-united in consortia to degrade the selected 
pharmaceutical to which they were previous exposed.   
This dissertation is divided in 5 chapters. The first one consists of a general 
introduction and literature review of the theme. The second chapter is dedicated to the 
material and methods. In the third and fourth chapters are presented the results, discussion 
and conclusions of the first and second experiment, respectively. The last chapter is 
dedicated to the general conclusions and future directions. 
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2. METHODS 
2.1. EXPERIMENTS 
2.1.1. Reagents and materials 
Paroxetine from Enzo Life Sciences, and Bezafibrate, methanol, acetonitrile and 
formic acid (98%) were acquired from Sigma-Aldrich. All remaining reagents were analytical 
grade or equivalent. 
All material used in both experiments were decontaminated or sterilized in order to 
avoid chemical and/or biological contaminations. Chemical decontamination was performed 
by immersing the material in a chloride acid bath for 24 h, being further washed with 
deionized water and placed at a warm house (40 ºC) to remove water present on the 
material. Biological sterilization was performed by autoclaving the material (120 ºC, 20 min). 
2.1.2. First experiment 
The samples to be used as inocula were collected in the Autumn (October, 2015) in 
two different compartments: sediments from the Douro estuary and activated sludge from 
a local WWTP (Fig. 3).  The collection was performed under sterile conditions and 
transported to the laboratory in the dark. The study consisted in two experiments in parallel, 
each one for the different type of sample.  
 
 
Once in the laboratory, a portion of each initial sample was frozen at -20 ºC for 
further analysis (DNA extraction for microbial community analysis).  
The remaining amounts were used for microcosms assembling. For this, samples 
(10 mL of activated sludge from WWTP or 10 g of estuarine sediment) were placed in flasks 
Figure 3 – Sampling sites at north bank of douro river 
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of 250 mL, containing four portions of mineral-salt medium (MM) (40 mL). This medium 
contained essential macro and micro nutrients, as inorganic salts and a buffer (Na2PO4), 
which provide the suitable conditions for metabolic activity, and consequently 
microorganisms growth (Amorim et al., 2014). Microcosms were then doped with Bzf or Prx 
(1 mg/L). For that a proper amount of a methanolic solution (prepared by dissolving a known 
amount of each compound in methanol) of each compound was added to the medium. 
Microcosms were supplemented with sodium acetate (500 mg/L) to promote 
microorganisms’ metabolic activity, generating a co-metabolism with the pharmaceutical 
compound.  
For each type of inoculum and compound tested, additional microcosms were 
assembled to identify some of the processes responsible for the pharmaceuticals removal. 
Adsorption controls were assembled, consisting in sterilized samples (by autoclaving) 
dissolved in MM, whereas the abiotic controls consisted only in sterilized MM, both doped 
with one pharmaceutical compound. Moreover, microcosms without addition of 
pharmaceutical compounds were assembled, acting as microbiological control, to evaluate 
how the microbial community adapted to incubation conditions. 
Microcosms were setup in triplicates and incubated at room temperature, in the dark. 
The incubation differed in terms of agitation conditions, with part of the microcosms in static 
conditions and the other in constant agitation (130rpm) (Fig. 4). 
 
 
To preserve the different consortia obtained at the end of the experiment, triplicates 
from each treatment were combined in a sterile tube. The consortia of all experiments were 
then preserved in glycerol (85%) at -80 ºC, for future reactivation. 
2.1.3. Second Experiment 
Based on the results obtained in first part of the study, three consortia of Bzf 
enrichment and two from Prx enrichment were isolated. Prx consortia isolation and 
Figure 4 - Scheme of microcosms setup 
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purification was performed for both inocula, but only for the cultures in static conditions (P1 
and P2, corresponding to estuarine sediments and activated sludge, respectively). 
Regarding Bzf, isolation was performed for both inocula for the cultures in static conditions 
(B1 and B2, corresponding to estuarine sediments and activated sludge, respectively), and 
for one culture from activated sludge under agitation conditions (B3). For that, several 
dilutions were prepared from the selected consortia, being inoculated following spread-plate 
method into plate count agar (PCA) media and MM enriched with the corresponding 
pharmaceutical (1 mg/L) and sodium acetate (500 mg/L), solidified by the addition of agar 
(15 g/L) (Fig. 5).  
After analyzing abundance and diversity of strains in plate media, through 
morphologic analysis, strains were purified in the respective medium by streak-plate 
method. Isolated strains were preserved in glycerol (85%) and at -80 ºC, and a sample of 
biomass was collected and frozen in sterile ultra-pure water for future DNA extraction and 
sequencing. 
To verify the efficiency of the isolated strains to degrade the pharmaceutical 
compound tested previously, isolated strains were inoculated in liquid MM (40 mL), doped 
with the respective pharmaceutical (1 mg/L) and supplemented with sodium acetate (500 
mg/L) (Fig. 5). For that, an equivalent portion of biomass was collected from the respective 
plate, until a final Optical density (OD) (λ=600 nm) between Abs=0.450-0.500. 
 
The experiment was assembled in triplicates and incubated in conditions similar to 
the previous experiments, i.e., consortia obtained from microcosms in agitation in the first 
experiment were maintained in agitation, and consortia from static conditions in first part 
were maintained in static conditions.  
Figure 5 - Scheme of microcosms set up with isolated strains 
Isolation and 
purification 
Microcosms 
inoculation and 
setup 
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2.1.4. Microcosms Operation 
Microcosms experiment was carried out for 7 feeding cycles of 2 weeks each in first 
experiment and 3 feeding cycles of 2 weeks in the second experiment. First feeding cycle 
started in the first day of the experiment, while the following feeding cycles started in the 
last day of the preceding (Fig. 6). During this process, microcosms were fed with sodium 
acetate (500 mg/L) twice a week, and to ensure the presence of oxygen in the microcosm 
each culture was transferred to a new sterilized flask, also twice a week. 
  
Figure 6 - Schematic example of microcosms operation, culture renewal and sampling 
 
Upon the end of each feeding cycle, 50% of each culture was transferred to a new 
microcosm vessel containing 20 mL of MM, being doped with the respective pharmaceutical 
compound, in the same dosage. The remaining solution was collected to determine 
pharmaceuticals removals in both experiments and microbial growth and the impact on the 
microbial community (2nd and 14th week), in the first experiment. Oxygen content in solution 
was measured in the end of the first experiment using an electrode for dissolved oxygen. 
2.2. ANALYTICAL DETERMINATIONS 
2.2.1. Microbial Growth 
Microbial growth was estimated by measuring the OD by spectrophotometry (VWR 
V-1200 spectrophotometer) at 600 nm at the beginning and at the end of each feeding cycle. 
In the beginning of the feeding cycle, a sample of the new culture was collected in order to 
follow microbial growth over the feeding cycle, while a sample of culture was collected from 
the remaining solution for future analyses. 
2.2.2. Pharmaceuticals Removal from solution 
To determine each pharmaceutical compound concentration, the solution collected 
at the end of each cycle was transferred into amber glass vials and centrifuge (at 2500 rpm). 
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The supernatant was then collected for further analysis by high-performance liquid 
chromatography (HPLC). Compounds analyses were carried out in a HPLC Beckam Coulter 
equipment (System Gold) provided with a diode array detector (module 168) and an 
automatic sampler (module 508). Compounds separation was performed in gradient mode 
with two eluents, water /formic acid, 99:1 (v/v) and acetonitrile (both previously degassed in 
an ultrasonic bath), with a flow rate of 1 mL/min, in a 100 mm x 4.6 mm Kinetex 2.6 µm C18 
column (Phenomenex, UK). Samples were injected in a volume of 50 µL and detector signal 
was monitored at λ=252 nm for Bzf and at λ=298 nm for Prx. For compounds quantification, 
a calibration curve with aqueous standard solutions (0.1 to 2 mg/L) of each compound was 
used. Each solution was prepared from stock standard solution prepared by dissolving a 
known amount of each compound in methanol. 
2.2.3. Fluoride Anion Release 
The quantification of fluoride anion concentration in solutions from Prx treatments 
was carried out using a fluoride ion-selective electrode (CRISON GLP21). A calibration 
curve was prepared using aqueous standard solutions (0.001; 0.0025; 0.005; 0.01; 0.02; 
0.1; 0.2 and 1 mM NaF). To minimize interferences, 10% of a total ionic strength adjustment 
buffer (TISAB II) solution was added to each sample. 
2.2.4. Bacterial community structure  
DNA was extracted from initial inocula (0.4-0.6 g) and from microcosms (solid 
phase) at the end of the first (2 weeks) (0.2-0.6 g) and last (14 weeks) (0.1-0.3 g) feeding 
cycles, using MO BIO PowerSoil kit. The efficiency of DNA extraction was monitored in 
electrophoresis in gel agarose 1.5%. 
Bacterial community structure was evaluated by ARISA, a rapid and effective 
technique that allows assessing microbial community diversity, being particularly useful for 
studies with spatial and temporal scales (Fisher and Triplett, 1999). This analysis requires 
PCR amplification of total DNA of the intergenic spacer region (ITS) (16S-23S) of rRNA 
operon genes. The intergenic region may encode tRNAs specific on the bacterial species, 
acting as an indicator of heterogeneity and also providing taxonomic resolution (Fisher and 
Triplett, 1999, Brown et al., 2015).  
DNA amplification used a set of primers specific for bacterial communities, ITSF (5′-
GTCGTAACAAGGTAGCCGTA-3’) and ITSReub (5′-GCCAAGGCATCCACC-3’) 
(Cardinale et al., 2004). PCRs were performed in duplicate reactions of 25 µL, containing 
0.4 µM of both primers, 0.2 mM of dNTP’s, 2.5 U Taq DNA polymerase, 1 mg/mL bovine 
serum albumin and 2-3.5 mM MgSO4. PCR products were visualized by electrophoresis in 
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gel agarose 1.5%, and purified using a purification kit (UltraClean 15 DNA Purification Kit, 
MO BIO Laboratories Inc.), being the purified product quantified by Quant-it HsDNA assay 
kit Qubit fluorometer (Invitrogen). Sample fragments were run on a ABI3730 XL genetic 
analyzer at STABVIDA Sequencing Facilities (Lisbon, Portugal). 
 
2.3. STATISTICAL ANALYSIS 
In each treatment, triplicates were analyzed and treated in separate, being the 
average and standard deviation values calculated for each treatment, at the different 
periods. 
ARISA fragment lengths were evaluated by Peak Scanner™ version 1.0 Software 
(Applied Biosystems). Data were transferred to an excel sheet and transformed in a matrix 
of aligned fragments, to be analyzed in PRIMER 6 software package (version 6.1.11). 
Fragments with fluorescence units inferior to 50 were rejected, being considered 
“background noise”. Fragments bellow 200 bp were not considered because they are 
considered to be too short ITS for bacteria. Bacterial richness and diversity indexes were 
calculated using Primer 6 software (version 6.1.13) to address the ecological description of 
community, wherein peaks number was representative of species number and peak height 
represented relative abundance of each bacterial species.  
To evaluate the community structure, the matrix was normalized using 
presence/absence pre-treatment function and samples were analyzed using Bray–Curtis 
similarity method, and then examined using a hierarchical cluster analysis. A 
multidimensional scaling (MDS) was obtained using default parameters with a minimum 
stress of 0.01 to generate a configuration plot based on percentage similarity. Microbial 
community similarity was evaluated through an analysis of similarity (two-way crossed 
ANOSIM, based on Bray-Curtis similarity), using PRIMER 6 software. This analysis is a 
permutation-based hypothesis statistical test, equivalent to univariate ANOVA, which tests 
for differences between groups of (multivariate) samples from different factors or 
experimental treatments (Danovaro et al., 2006).  
Statistic tests were performed using commercial software Statistica, version 13, Dell 
Inc. (2015). For pharmaceuticals concentrations, defluorination rates, bacterial richness and 
diversity significant differences among samples were calculated through a non-parametric 
analysis, and significant differences (p<0.05) were detected by Kruskal-Wallis ANOVA 
multiple comparisons test.  
30 
 
 
 
 
 
 
CHAPTER 3 
BIOREMEDIATION OF BEZAFIBRATE AND 
PAROXETINE BY MICROORGANISMS FROM A 
WASTEWATER TREATMENT PLANT AND 
ESTUARINE SEDIMENTS 
 
 
 
31 
 
3. BIOREMEDIATION OF BEZAFIBRATE AND PAROXETINE BY 
MICROORGANISMS FROM A WASTEWATER TREATMENT PLANT AND 
ESTUARINE SEDIMENTS 
 
3.1. RESULTS 
The maintenance of all microcosms was performed under sterilized conditions, 
being incubated at room temperature (20ºC) and in the dark. Microcosms’ incubation only 
differed in agitation conditions. Microcosms with the same pharmaceutical compound were 
incubated in static conditions and under agitation conditions (1300 rpm). Agitation 
conditions influenced the oxygenation of the microbial cultures, however the presence of 
oxygen in microcosms was also influenced by flask renewal twice a week. Indeed, in 
microcosms under agitation conditions, oxygen dissolved in solution had higher 
concentration values (8.67-9.37 mg/L) than in microcosms under static conditions (4.74-
5.13 mg/L). 
The results reported in this section are in terms of microbial community structure 
and pharmaceutical removal from solution. The latest includes results from microbial 
cultures as well as results regarding pharmaceuticals adsorption potential to sediments and 
cells and degradation/removal by abiotic processes. Complementary analyses of fluoride 
anion released in experiments with Prx are also reported. 
3.1.1. Pharmaceuticals Removal 
Pharmaceuticals removal from microbial cultures was evaluated by analyzing 
samples of the liquid portion of the microcosms for both inocula. These data are 
complemented with analysis of abiotic and adsorption controls solution. The experiment 
had the duration of 14 weeks, adsorption potential experiment was only performed for 10 
weeks, due to the complete removal of solid particles and cells by renewal cycles, making 
unfeasible the continuation of the trial.  
3.1.1.1. Bezafibrate 
3.1.1.1.1. Cultures enrichment 
Removal percentages of Bzf from solution (Fig. 7) showed that incubation conditions 
had a greater effect in removal efficiency than the origin of the inocula. Indeed, in static 
conditions (Fig. 7A) Bzf showed high removal rates over time, never being detected in 
solution (<0.03 mg/L), in microcosms containing activated sludge or estuarine sediments, 
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leading to estimated removal above 97%. In agitation conditions (Fig. 7B) different 
responses according to the inoculum origin and experimental time were observed. Actually, 
after two weeks of the experiment Bzf was only partial removed from solution: 30±7 % and 
86±3 % for activated sludge and estuarine sediments, respectively. Removal efficiency 
improved over time, reaching a steady state, with no compound detection in solution (<0.03 
mg/L), after six weeks of the experiment, in case of microcosms inoculated with activated 
sludge, or after 8 weeks of experiment, in case of microcosms inoculated with estuarine 
sediments.  
 
 
3.1.1.1.2. Abiotic Degradation and Adsorption Potential 
The results obtained from the analysis of abiotic controls (only culture medium 
without inocula) indicated that Bzf is not degraded by abiotic processes, since it was 
Figure 7 -  Removal percentages (average and standard deviation, n=3) of Bzf from solution in 
microcosms with both inocula (Green – Activated Sludge, Blue – Estuarine Sediment), under 
both incubation conditions (A – Static, B – Agitation)  
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detected in the expected concentration in solution (1 mg/L). Furthermore, differences were 
not observed in the different incubation conditions.  
Regarding Bzf adsorption potential, no significant tendency to be adsorbed to 
sterilized cells or sediment was observed, in either incubation conditions. In fact, only in 
some sporadic cases Bzf in solution was lower than doped concentrations (concentration 
range 0.7-1 mg/L, results not shown), however these values corresponded to a few replicas 
in the several analyses performed, and the tendency was not observed in the following 
sampling times.  
3.1.1.2. Paroxetine 
3.1.1.2.1. Enrichment culture 
Removal percentage of Prx was, in general, not affected by the different incubation 
conditions (Fig. 8). Under static conditions (Fig. 8A) Prx was not detected (<0.03 mg/L) in 
solution during the time of the experiment either in microcosms of activated sludge or 
estuarine sediment. In agitation conditions (Fig. 8B), although in microcosms from estuarine 
sediment Prx was not detected in solution, it was not completely removed in microcosms 
inoculated with activated sludge after 2 weeks of the experiment (ca. 94% removal). But, in 
this late case, the maximum removal efficiency (Prx concentration <0.03 mg/L) was 
achieved in the following cycles. 
3.1.1.2.2. Abiotic Degradation and Adsorption Potential 
Prx demonstrated to be degraded by abiotic processes. After two weeks of 
experiment, Prx showed abiotic removal of 63% and 60% in static and agitation conditions, 
respectively. In the following sampling periods, these values decreased and remained 
stable (ca. 45%) during the remaining time of the experiment. 
Analyzing the results obtained from adsorption controls it is possible to verify that 
Prx had potential to be adsorbed by particles. Since adsorption controls consisted in 
sterilized inoculum, biomass growth did not occur. Thus, Prx adsorption potential varied in 
function of the presence of particles, which decreased over time due to the medium renewal 
that were performed at the end of each period of two weeks (Fig. 9). In fact, two weeks after 
the beginning of the experiment, Prx was not detected in solution in microcosms with 
sterilized estuarine sediment, while in microcosms with sterilized activated sludge it was 
detected but in very low amounts (0.07 mg/L).  
In the case of the adsorption controls with estuarine sediment, this tendency 
continued until week 6 after the beginning of the experiment, with Prx not being detected. 
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Only after 10 weeks it was possible to detect Prx in solution (removal of 54% and 69% in 
static and agitation conditions, respectively). At this time, solution was found to be very clear 
(OD~0.030, λ=600 nm), since sediments particles were largely removed from solution due 
to repeated medium renewal each two weeks.  
 
 
Figure 8 - Removal percentages (average and Standard Deviation, n=3) of Prx from solution 
in microcosms with both inocula (Green – Activated Sludge, Blue – Estuarine Sediment), 
under both incubation conditions (A – Static, B – Agitation) 
 
Regarding adsorption controls of activated sludge, at week 6, a large part of the 
particles was already removed from solution, being possible to detected Prx in solution. 
Incubation conditions had no effect in the adsorption potential, with removal percentages of 
75% and 65% in static and agitation conditions, respectively. Removal percentages were 
even lower after 10 weeks.  
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3.1.2. Fluoride Anion Release 
Since Prx is a fluorinated compound, the quantification of fluoride anion in solution 
can act as an indicator of the degradation of this pharmaceutical. However, the presence of 
organic particles and sediments interfered with the measurement of this parameter until 4 
weeks after inoculation with activated sludge and after 8 weeks in microcosms inoculated 
with estuarine sediment (Table 5).  
In general, microcosms with activated sludge presented high values of defluorination 
efficiency, at week 6. However, it was in static conditions that defluorination efficiency 
reached the higher values. In agitation conditions, it is possible to verify that defluorination 
efficiency increased with experimental time. 
Figure 9 - Removal percentages (average and standard deviation, n=3) of Prx from solution in 
adsorption controls for both sterilized inocula (Green – Activated Sludge, Blue – Estuarine 
Sediment), under both incubation conditions (A – Static, B – Agitation) 
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Analysis performed in abiotic controls indicated that defluorination did not occurred 
by abiotic processes (fluoride anion not detected in solution), indicating that the release of 
fluoride anion only occurred through biologic processes.   
 
Table 5 - Percentage of defluorination percentage (mean and standard deviation, n=3) in 
microcosms enriched with Paroxetine, over time 
 
 
3.1.3. Biomass Growth 
Biomass growth was estimated at the end of each feeding cycle, by 
spectrophotometry, at a wavelength of 600 nm, to understand how the community adapted 
to incubation conditions. The method measures the turbidity of the culture, which is an 
indicator of the biomass growth and how well distributed it is in the medium. 
These results indicated that incubation conditions affected the biomass growth of 
activated sludge microorganisms (Fig. 10). Indeed, microbial cultures with and without 
pharmaceutical addition showed to be affected by agitation in the first weeks of the 
experiment (Fig. 10B), while in static conditions growth was favored in cultures in the same 
period (Fig. 10A). In static conditions a much higher biomass growth was observed in 
microbial culture enriched with Prx comparing with control. Over time, these cultures 
showed a certain tendency to stabilize. 
            Condition 
 
 
         Week 
Activated Sludge Estuarine Sediment 
Static Agitation Static Agitation 
6 65±7 49±10 - - 
8 86±6 39±7 - - 
10 62±2 46±7 74±9 11±11 
12 100±0 49±13 72±10 42±17 
14 79±29 78±11 86±4 58±3 
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Figure 10 - Optical density (Abs at 600nm), measured over time, of cultures of activated sludge 
enriched with Bzf (Blue), Prx (Green) or without pharmaceutical addition (control) (Yellow) 
under both incubation conditions. A – Static, B – Agitation 
 
For the cultures inoculated with estuarine sediment, biomass growth was only 
determined after 8 weeks of the experiment, since the presence of sediments interfered 
with the selected method. From this period on, it is possible to verify that, similarly to what 
occurred in microcosms from activated sludge, incubation conditions influenced biomass 
growth (Fig. 11). In fact, microcosms with the same treatment demonstrated a tendency to 
have higher biomass growth under static conditions than under agitation conditions. In static 
conditions, microcosms enriched with pharmaceuticals presented a clear tendency to have 
higher growth than the control in the same conditions (Fig. 11A). However, differences 
between treatments were not observed in agitation conditions (Fig. 11B). After 10 weeks of 
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experiment, flocculation occurred in microcosms under agitation conditions, with or without 
pharmaceutical enrichment. This can indicate the maladjustment of the community to the 
incubation conditions. 
 
3.1.4. Bacterial Richness and Diversity 
The indexes of diversity and richness were calculated for each treatment, through 
ARISA profile in initial samples and samples collected after 2 and 14 weeks of incubation.  
Richness results showed variations with treatment, incubation and time. However, it 
is possible to notice that initial samples of estuarine sediment have higher richness 
comparing with activated sludge. Furthermore, in Fig. 12 it is possible to observe that 
richness decreased in all samples of estuarine sediment, comparing to the initial value. 
Figure 11 - Optical density (Abs at 600nm), measured over time, of cultures of estuarine 
sediment enriched with Bzf (Blue), Prx (Green) or without pharmaceutical addition
(control) (Yellow) under both incubation conditions. A – Static, B – Agitation 
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Microcosms enriched with activated sludge and Prx had to have different values of richness 
among incubation conditions (p<0.05), being this tendency intensified with time.  
In terms of diversity indexes, he present results showed significant differences 
(p<0.05) between estuarine sediment in microcosms and initial sediment, with a loss in 
diversity (Fig. 13). Time also affected the diversity. Indeed, a decrease in diversity occurred 
at 14 weeks, however only in static conditions. Furthermore, the effect of Bzf was more 
effective than Prx comparing to control. However, this effect varied among conditions. 
 
 
Figure 12 - Bacterial richness along experiment time. II – Initial inoculum; C - Control, Bzf – 
Bezafibrate treatment; Prx – Paroxetine treatment; WWTP – Inoculum from WWTP sludge; 
ES – Inoculum from estuarine sediment. a – significant differences comparing with 
respective control (p<0.05); b – significant differences among same treatment, at different 
time (p<0.05); c – significant differences among same treatment, with different incubation 
conditions (p<0.05); d – significant differences between microcosm and initial samples 
(p<0.05) 
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3.1.5. Bacterial Community Structure 
ARISA analysis was performed to characterize the bacterial community of the initial 
inocula and of the different treatments along the experiment. For each sample, ARISA 
fragment length (AFL) profiles were obtained. Different peaks correspond to different 
fragment lengths and therefore to different bacteria phylotypes. Differences in their genetic 
structure, or more specifically in the distribution of the different phylotypes among the 
different samples, are the most relevant feature.  
Bacterial community evolution was evaluated based on similarity between samples 
with different pharmaceutical addition treatment, incubation conditions and time of 
experiment. Through ARISA results, two clusters were obtained for the bacterial community 
of each inoculum (Fig. 14), one for week 2 (Fig. 14A, Fig. 14C) and another for week 14 
(Fig. 14B and Fig. 14D). Cluster analysis exhibit a good experimental replication as, for 
each treatment, replicates were clustered together, with one only exception. Samples are 
mainly grouped by incubation conditions (static or agitation), and, inside these groups, 
Figure 13 - Bacterial diversity along experiment time. II – Initial inoculum; C - Control, Bzf – 
Bezafibrate treatment; Prx – Paroxetine treatment; WWTP – Inoculum from WWTP sludge; ES 
– Inoculum from estuarine sediment. a – significant differences comparing with respective 
control (p<0.05); b – significant differences among same treatment, at different time (p<0.05); c 
– significant differences among same treatment, with different incubation conditions (p<0.05); 
d – significant differences between microcosm and initial samples (p<0.05) 
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higher similarity was observed among samples with pharmaceutical treatment comparing 
to control, except for sludge community, under static conditions at week 2. 
 
 
 
 
Two MDS ordinations plots were assembled, for bacterial community of each 
inoculum (from estuarine sediment and from activated sludge), to visualize variation under 
different incubation conditions (static or agitation) (Fig. 15A; Fig. 16A) and variation along 
experiment time (2 and 14 weeks) (Fig. 15B; Fig. 16B).  
Analyzing MDS ordinations, it is possible to observe that samples are grouped by 
time and that samples from the initial inocula are more similar to the samples from week 2 
than to those of week 14. On the other hand, ordinations confirmed the division of samples 
according to the incubation conditions (static vs. agitation). 
 
Figure 14 - Hierarchical clustering based on Bray-Curtis similarities from ARISA fingerprints of 
bacterial communities inoculated from activated sludge (A and B) and estuarine sediment (C and 
D) after 2 weeks (A and C) and 14 weeks (B and D) of experiment. S – Static; Ag – Agitation; C – 
Control; B – Bezafibrate treatment; P – Paroxetine treatment 
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To understand the factors responsible for the shaping of the bacterial community 
structure, analysis of similarities (two-way crossed ANOSIM) was performed. Results 
showed a significant effect of both time and incubation conditions with significant differences 
among the different groups of samples (Table 6). For each experimental time (week 2 and 
week 14), the factor treatment showed to be the most important for the structure of the 
community, alongside with incubation conditions. Indeed, results indicate that whatever the 
origin of the inocula (WWTP or estuarine sediments), Bzf and Prx had a significant effect 
on bacterial community structure, either after 2 or 14 weeks of experiment.  
Figure 15 - Multidimensional scaling (MDS) ordination based on Bray-Curtis similarities from 
ARISA fingerprints of bacterial communities originated from estuarine sediments. A – Effect 
of incubation conditions; B – Effect of time. Ag – Agitation; S – Static; II – Initial Inoculum; C 
– Control; B – Bezafibrate treatment; P – Paroxetine treatment; 2 and 14 correspond to 
sample time in weeks, 0 is applicable to initial sediment 
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Figure 16 - Multidimensional scaling (MDS) ordination based on Bray-Curtis similarities from 
ARISA fingerprints of bacterial communities originated from activated sludge. A – Effect of 
incubation conditions; B – Effect of time. Ag – Agitation; S – Static; II- Initial Inoculum; C – 
Control; B – Bezafibrate treatment; P – Paroxetine treatment; 2 and 14 correspond to sample 
time in weeks, 0 is applicable to initial sludge 
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Table 6 - Two-way crossed ANOSIM test for different time of exposure (week 2 and week 
14), incubation conditions (static vs. agitation) and treatment (C – Control; Bzf – 
Bezafibrate; Prx – Paroxetine) effect, based on ARISA results from bacterial 
communities inoculated from activated sludge (AS) and estuarine sediment (ES) 
 
 
Statistic 
value (R) 
Significance  
level (%) 
 TIME VS INCUBATION 
ES 
Time 0.727 0.1 
 
Incubation 0.663 0.1 
AS Time 0.842 0.1 Incubation 0.792 0.1 
 
TREATMENT VS INCUBATION – 2 WEEKS 
ES 
GLOBAL TEST    
INCUBATION 1 0.2 
TREATMENT 0.840 0.1 
PAIRWISE    
BZF, C 1 1 
BZF, PRX 0.778 1 
PRX, C 0.778 1 
AS 
GLOBAL TEST    
INCUBATION 1 0.2 
TREATMENT 1 0.1 
PAIRWISE    
BZF, C 1 1 
BZF, PRX 1 1 
PRX, C 1 1 
 
TREATMENT VS INCUBATION – 14 WEEKS 
ES 
GLOBAL TEST    
INCUBATION 1 0.3 
TREATMENT 1 0.1 
PAIRWISE    
BZF, C 1 1 
BZF, PRX 1 1 
PRX, C 1 1 
AS 
GLOBAL TEST    
INCUBATION 1 0.3 
TREATMENT 0.992 0.1 
PAIRWISE    
BZF, C 1 1 
BZF, PRX 1 1 
PRX, C 0.981 1 
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3.2. DISCUSSION 
In the last years several authors published studies regarding pharmaceuticals 
removal in WWTPs, including Bzf and Prx. However, there is a lack of knowledge regarding 
removal processes. Indeed, pharmaceuticals removal from solution may be due to: i) 
complete degradation of the parental compound, ii) formation of intermediate products or 
iii) formation of (bio)transformation products (Musson et al., 2010, Jelic et al., 2011). 
Several studies reported the capacity of microorganisms to remove pharmaceuticals 
(Yu et al., 2006), pesticides (Barra Caracciolo et al., 2013, Wang et al., 2016), toxic 
metalloid (Dey et al., 2016), hydrocarbons (Ribeiro et al., 2013, Abed et al., 2014, Sheu et 
al., 2016), and other chemical compounds (Carvalho et al., 2006, Zhu et al., 2007) from the 
medium, using isolated bacterial strains or bacterial consortia, which are usually obtained 
from known contaminated sites. 
Although there are a few reports of Prx occurrence in WWTP effluent and superficial 
water (Schultz and Furlong, 2008, Wu et al., 2009), studies demonstrated that Prx can be 
efficiently removed from wastewater after treatment in WWTP (Schlüsener et al., 2015). On 
the other hand, environmental occurrence of Bzf has been reported by several authors 
(Lindqvist et al., 2005, Fent et al., 2006, Luo et al., 2014). Its removal rate in WWTP is not 
consensual among the different studies published, since removal rates are reported in a 
range from 10 to 75% (Jelic et al., 2011, Luo et al., 2014). 
Sorption of a compound is usually predicted by its hydrophobicity and electrostatics 
interactions. Hydrophobicity, expressed as log Kow, is usually used to predict fate of 
micropollutants, while electrostatic interaction will translate the behavior of a certain 
chemical under different pH conditions (Tang et al., 2014). Considering the high Kow value 
of Bzf, it was expected that it would adsorb to sediments or cells, which did not occur in the 
present study. In fact, in adsorption controls Bzf was detected in very high concentrations 
in solution. In contrast with the present study, Tang et al. (2014) reported that Bzf adsorption 
was 16% and Jelic et al. (2011) reported an adsorption of 2%. But Calisto et al. (2015) 
highlighted the importance of pH, and how it influences the chemical structure of the 
compound. Adsorption capacity of Bzf can be affected by pH. Indeed, at neutral pH, studies 
showed that it did not adsorb due to electrostatic repulsive forces exerted by the negative 
electricity of the compound (Tang et al., 2014, Semblante et al., 2015).  
Present results showed that Bzf was removed from solution in microcosms 
experiment, with microorganisms having an important role. In fact, Bzf was removed from 
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solution in high amounts, and considering its low adsorption, one can assume it was 
degraded by microorganisms. According to these results, Tang et al. (2014) reported the 
degradation of Bzf by activated sludge, and Collado et al. (2014) reported a high removal 
of this compound in secondary treatment of WWTP. There is a lack of information regarding 
Bzf degradation on estuarine environment, however, degradation by microorganisms from 
contaminated sites is well-stablished in laboratory conditions (Quintana et al., 2005, Tang 
et al., 2014). Abiotic controls were assembled to verify if degradation occurred through biotic 
or abiotic processes. Results indicated that Bzf was not significantly degraded by abiotic 
processes. Luo et al. (2014) reported that Bzf was very resistant to ozonation. Furthermore, 
Trovó et al. (2008) reported that Bzf was not degradable under solar irradiation, due to its 
incapability to absorb light above 300nm. This characteristic of Bzf can be related with its 
chemical structure, since chemical compounds with amide bonds (RCONR2) are hardly 
degraded by UV light (Kim and Tanaka, 2009), indicating the resistance of this compound 
to abiotic degradation.  
The present results indicated that Bzf was removed from solution either in 
microcosms with activated sludge or estuarine sediments. However, higher removal 
efficiencies were observed in static conditions, indicating that incubation conditions affected 
microorganisms’ performance. Time also influenced the removal efficiency in agitation 
conditions, indicating that in these conditions microorganisms needed an adaption phase. 
In the present study, Prx was not detected in solution after 2 weeks of experiment 
and in any of the following cycles, in the different experimental conditions, either in the 
presence of estuarine microorganisms or activated sludge microorganisms. Nevertheless, 
according to our results, Prx was removed by adsorption and by abiotic degradation. Other 
authors (Kwon and Armbrust, 2008) reported that SSRIs have an adsorption capacity above 
91%, while other studies have reported presence of Prx in biosolids and sediments 
(Radjenović et al., 2009, Wu et al., 2009, Chari and Halden, 2012). This behavior is in line 
with the predicted by the Kow value. However, Prx high solubility in water can promote the 
formation of the molecule cationic form. Since adsorption is a natural process, adjusted by 
electrostatic interactions and dependent of the compound physicochemical properties, ionic 
biding and hydrophobic interactions with soil particles in solution can be promoted (Kwon 
and Armbrust, 2008, Brown et al., 2015). Organic carbon has a straight relationship with 
adsorption process in distinct environmental scenarios, as activated sludge, soils and 
aquatic environments (Semblante et al., 2015). According to KD value, Prx has a great 
tendency to adsorb either to sludge or to natural sediments containing OC (Brown et al., 
2015). Actually, at environmental pH values (pH=7), positively-charged forms adsorb to OC 
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(negatively charged), through electrostatic interactions that are involved in adsorption 
process, being retained in sediments/sludge (Brown et al., 2015, Semblante et al., 2015). 
In abiotic controls, Prx was not detected in liquid phase until the total removal of 
sediments/cells, which can be explained by the potential sorption to particles. This 
characteristic of Prx can act as a limiting factor regarding its bioavailability in the water 
phase in the presence of solid material. On the other hand, sorption can also contribute to 
the biodegradation of compounds in the solid medium, since the interactions with bacterial 
surface can favor the uptake into cells or the interaction between the compound and the 
extracellular enzymes (Semblante et al., 2015). 
Our results indicated that Prx was removed in abiotic controls. Actually, 
pharmaceuticals can undergo abiotic transformations, although there are limitations 
associated with this process. Volatilization, hydrolysis and photolysis are the most common 
in the environment, however SSRIs compounds, as Prx, are not volatile, being more 
probably subjected to chemical degradation (Vasskog et al., 2009, Semblante et al., 2015). 
Kwon and Armbrust (2008) reported that Prx is not degraded by hydrolysis, however 
sunlight degrades it, being this process accelerated by the alkalization of the solution. 
Actually, it was reported that Prx is a photo-labile compound that absorbs light at 
wavelengths above 290 nm, being directly affected by photolysis (Kwon and Armbrust, 
2008, Brown et al., 2015). On the other hand, in environmental conditions Prx is not affected 
by direct photolysis due to the adsorption properties. The unavailability in solution allied with 
the natural organic matter in water, which undermines UV light penetration, will limit the 
action of photolysis (Kwon and Armbrust, 2008). Since microcosms were kept in the dark 
during experiment time, degradation of Prx by photolysis cannot be considered for the 
removal of the compound in abiotic controls.  
Results indicated that Prx can be removed by adsorption, and be degraded by both 
biotic and abiotic processes. It was possible to verify that adsorption decreased over time, 
due to particles removal and its presence was very low after 10 weeks of experiment. At 
this time (10 weeks), Prx removal value in abiotic controls was similar to that observed in 
adsorption controls. Therefore, in inoculated microcosms the remaining Prx removal 
observed was probably due to biologic processes. 
Vasskog et al. (2009) measured CO2 produced and O2 consumed, in an aerobic 
treatment with the purpose to estimate Prx removal from sewage, while (Bergersen et al., 
2012) measured the biogas produced by microorganisms and demonstrated that Prx can 
be biodegraded in anaerobic conditions. In both studies, Prx was highly removed, being the 
compound with the highest removal rate, but its biodegradation showed to be more efficient 
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in anaerobic conditions. This information is consistent with the present work, evidencing Prx 
degradation under different oxygen conditions. In fact, in both incubation conditions, either 
agitation, with an aerobic environment, and in static with a reduced amount of oxygen, Prx 
degradation was observed.  
Removal of the halogen substituent from a compound is a fundamental reaction that 
occurs during its biodegradation (Carvalho et al., 2006, Amorim et al., 2013). Our results 
indicated that the presence of fluoride anion in solution was higher in static conditions either 
in cultures from activated sludge or estuarine sediment. However, time improved fluoride 
anion release in agitation conditions. These results indicate once more that the conditions 
of incubation and time affected the performance of the microorganisms. 
Fluoride anion concentration results also corroborate the biotic degradation of Prx. 
In our study, the fluoride anion release suggests the presence of an enzyme with the 
capability to dehalogenate Prx. In fact, the absence of fluoride anion release in abiotic 
controls enhances this argument. However, a non-stoichiometric relation between fluoride 
anion release and Prx initial concentration was observed, which can be due to the formation 
of Prx transformation products, in which fluoride anion is incorporated, as reported in 
(Amorim et al., 2013). These results indicate that Prx degradation was probably not 
complete, particularly in abiotic conditions.  
The implementation of an external energy source (carbon) can enhance the 
efficiency of defluorination due to increasing growth of cells, and consequently decrease 
the time for removal of the contaminant occur (Amorim et al., 2013, Amorim et al., 2014, 
Carvalho et al., 2016). Carvalho et al. (2016) used a single strain to study the biodegradation 
of moxifloxacin, obtaining high defluorination values (92%) due to the use of acetate as a 
bulk substrate, increasing the number of microorganism capable to react with the 
pharmaceutical. The same external energy source was used in the present study. 
Acclimation of microorganisms to the incubation condition can act as a limiting factor 
to their degradation capacity. In our results, it is possible to verify the existence of different 
tendencies in biomass growth, mostly regarding the incubation conditions. Studies reported 
that the use of an additional source of carbon can enhance the microbial growth, instigating 
pharmaceutical removal (Amorim et al., 2014, Carvalho et al., 2016). Veach et al. (2012) 
reported that biomass growth was significantly affected by the presence of the 
pharmaceuticals. However, in the present study biomass growth was not significantly 
affected by pharmaceuticals presence. Indeed, in certain instances, biomass growth in 
controls was lower to the one verified in microcosms enriched with pharmaceutical, 
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indicating an extra energy source. So, these results indicated that microorganisms were 
resistant to both selected pharmaceutical compounds and that they were able to degrade 
them. 
Microbial communities are ubiquitous organisms, responsible for the primary 
response to ecosystem perturbations. Thus, microorganisms, including bacteria, are 
vulnerable to exogenous physicochemical and biological stressors (Oladele, 1999, 
Juwarkar et al., 2010). Microcosms are considered ecosystems models, in which is possible 
to set specific conditions to understand the effect of a pollutant in microbial communities 
(Barra Caracciolo et al., 2013). In this study, microbial richness and diversity was measured, 
using ARISA, before and during the experiment. The response of bacterial community 
originated from activated sludge and from estuarine sediment was then evaluate regarding 
the presence of pharmaceuticals, time and incubation conditions.  
Results from bacterial richness and diversity demonstrated that variations occurred, 
however they did not follow any pattern in the different parameters analyzed. At the end of 
week 2, it was possible to verify that the microbial communities present in microcosms with 
activated sludge and under Bzf treatment, had a diversity index superior to the one in control 
(without pharmaceutical addition), stabilizing over time. The decrease in microbial diversity 
in sediments from microcosms compared to initial sediment can be an indicator of the 
capability of the pharmaceutical to act as a selective force. The presence of significant 
differences among some samples in terms of diversity indicates that the community had the 
ability to adapt to the presence of these compounds.  
Shifts on bacterial community structure were analyzed by ARISA, a tool useful to 
study the genetic structure of complex communities, through DNA fingerprinting. Time was 
one of the factors that affected communities, as it is possible to verify by the decrease in 
similarity of communities exposed to the same pharmaceutical compound and incubation 
conditions. Indeed, the presence of sediment at week 2 and its absence at week 14, can be 
relevant for these results, since microbial degraders are more commonly associated to 
surface of sediments and sediments lost can results in loss of some species (Wang et al., 
2016). Results showed that incubation conditions also had a relevant effect in microbial 
community with clear differences between conditions. In each period, samples from static 
incubations were grouped together among them, the same occurring for samples from 
agitation incubations, for microbial communities with different origins. These differences are 
in accordance with what was visualized during all the experiment, agitation cultures soon 
started to flocculate, while static cultures have kept a turbid solution during experiment time, 
indicating stress signs from agitations conditions. Agitation promoted the incorporation of 
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oxygen in the liquid media, while in static conditions oxygen saturation had lower values. 
Oxygen content is considered an abiotic factor, capable of influencing the metabolic 
activities of microorganisms (Tran et al., 2013). Furthermore, oxygen can be used as an 
electron acceptor, stimulating microbial degradation of pollutants (Juwarkar et al., 2010). 
Indeed, shifts in bacterial community occurred over time, promoting the emergence of a 
different bacterial community, able to degrade Bzf. In fact, Bzf degradation increased with 
time. Communities exposed to Prx also experienced shifts. In fact, although the compound 
removal from solution did not change over time, defluorination improvement suggests that 
a microbial community able to dehalogenate Prx with more efficiency emerged.   
Analysis of similarity showed statistically significant effect of time. Presence of 
pharmaceutical compound and incubation conditions on microbial communities also 
showed to be statistically significant in each time period. Despite a few studies reporting the 
environmental presence of Bzf and Prx, the effect of these pharmaceuticals on microbial 
communities is not well known. However, since pharmaceutical compounds are designed 
to be biologically active, it is possible that they are capable of causing effects in living 
organisms (Boxall, 2004, Barra Caracciolo et al., 2015). Thus, bacterial community can be 
affected by the presence of these compounds and their toxic effects. Fernandes et al. 
(2015), reported that estuarine communities can be affected by the presence of 
enrofloxacin, while Chen et al. (2014) reported, in their study, that variations on bacterial 
community present in sludge can occurred during pharmaceuticals removal. Sensitive 
species may be eliminated, while resistant species will have the ability to proliferate, since 
they are capable to produce degradative enzymes. Microbial consortium can also be 
constituted by resistant bacteria, capable of using secondary products, participating also in 
biodegradation processes (Oladele, 1999). 
3.3. CONCLUSIONS 
The results obtained in this experiment demonstrated the efficiency of autochthonous 
microorganisms derived from estuarine sediments and associated WWTP for the removal 
of the selected pharmaceuticals (Bzf and Prx). Despite Prx can also be removed by 
adsorption to particles and by abiotic processes, microorganism’s presence is essential to 
the dehalogenation of the molecule.  
The evaluation of community structure demonstrated that time, incubation conditions and 
pharmaceutical treatment influenced the bacterial community present in microcosms. This 
effect did not affect the capability of removing the pharmaceuticals, which, in some cases, 
increased with time. 
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PHARMACEUTICAL ENRICHED CONSORTIA 
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4. BIOREMEDIATION EFFICIENCY OF MICROORGANISMS ISOLATED FROM 
PHARMACEUTICAL ENRICHED CONSORTIA 
 
4.1. RESULTS 
The obtained results reported at this section were obtained from the second 
experiment of this work. The aim of this experiment was to evaluate the efficiency of isolated 
strains, obtained from solution culture at the end of experiment one, in degrading the 
pharmaceuticals in study.  
Results are reported for the 5 consortia of isolates : two consortia derived from Prx 
enrichment, under static conditions, in which one was obtained from estuarine sediment 
(P1) and the other from activated sludge from WWTP (P2) inocula, two consortia derived 
from Bzf enrichment, under static conditions, in which one was obtained from estuarine 
sediment (B1) and the other from activated sludge from WWTP (B2) inocula, and another 
consortia was derived from Bzf enrichment, under agitation conditions, obtained from 
activated sludge from WWTP inoculum (B3). 
In this section, the results reported are in terms of number of different colonies per 
consortia, obtained in solid media, either in MM-pharmaceutical and PCA, pharmaceutical 
removal percentages in microcosms inoculated with the consortia of isolated colonies, and 
fluoride anion release in Prx treatments. 
4.1.1. Isolated bacterial strains 
Bacterial strains were isolated from the different consortia in solid-medium plates to 
assess the different phenotypes present. At first, 100 µL of each microbial culture solution 
(dilutions of 1x10-4), obtained in the first experiment, were spread in a plate media. The 
inoculation of the different media allowed to estimate the different cultivable bacteria able 
to grow in a medium in which the pharmaceutical is present, as well as the number of 
colonies present in the whole consortium.  
Present results indicate that the number of colonies with different phenotypes was 
higher in PCA media, comparing with the number of microorganisms obtained in MM-
pharmaceutical media (Table 7). The number of colonies obtained in PCA medium was 7 
for the two consortia originated from Prx enrichment culture under static conditions (P1 and 
P2), 6 for the two consortia originated from Bzf enrichment culture under static conditions 
(B1 and B2), and 9 for the consortia originated from Bzf enrichment culture under agitation 
conditions (B3). On the other hand, in the medium enriched with each of the pharmaceutical 
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compounds (MM-pharmaceutical) the number of colonies observed varied between 2 (P2), 
3 (P1, B2, B3) and 4 (B1) phenotypes. So, the number of isolated bacterial strains present 
in each consortium able to grow in the presence of each pharmaceutical compound does 
not correspond to the total number of phenotypes present in the respective consortium. 
Furthermore, the origin of the consortium also influenced the number of microorganisms 
able to proliferate in a contaminated medium. The incubation conditions, and indirectly the 
amount of oxygen present in the medium, also influenced the number of different strains 
developed. 
 
Table 7 - Bacterial strains isolated from the different consortia in PCA media (Blue) 
and MM-pharmaceutical media (Yellow). (x) indicates the presence and (-) the 
absence. P1 – Paroxetine, Estuarine Sediments, Static; P2 – Paroxetine, Activated 
Sludge, Static; B1 – Bezafibrate, Estuarine Sediments, Static; B2 – Bezafibrate, 
Activated Sludge, Static; B3 – Bezafibrate, Activated Sludge, Agitation 
 
4.1.1. Pharmaceuticals Removal 
Pharmaceuticals removal percentage was determined through the analysis of the 
concentration of each pharmaceutical compound in microcosm solution.  
Three consortia potentially able to degrade Bzf, originated from the first part of this 
work, were reconstructed in new culture medium. So, the microbial communities were 
previously exposed to Bzf presence. Results (Fig. 17) showed that Bzf removal percentage 
(79%) in consortium derived from the estuarine sediment, B1, after 2 weeks, was 
significantly (p<0.05) higher than the removal percentage observed for the consortia 
obtained from the activated sludge, B2 (31%) and B3 (57%). For B1, removal percentages 
were higher than 97% (Bzf not detected in solution) in following weeks, the same being 
noticed for B2. As for consortium B3, the only maintained under agitation conditions, despite 
the considerable Bzf removal percentage observed at the end of the 2nd week, Bzf removal 
decreased and by the end of the 6th week it was only of 23%. 
 
 
  
 
Colony Identification Number 
Co
n
so
rt
iu
m
 
 
 1 2 3 4 5 6 7 8 9 10 11 12 
 P1 X X X X X X X X X X - - 
 P2 X X - X X X X X X X - - 
 B1 X X X X X X X X X X - - 
 B2 X X X X X X X X X - - - 
 B3 X X X X X X X X X X X X 
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The reconstruction of two consortia potentially able to degrade Prx was performed 
using the microbial cultures of microcosms previously exposed to Prx in static conditions. 
Results (Fig. 18) indicate that high Prx removal percentage (93%) was obtained after 2 
weeks of experiment for the consortium obtained from the estuarine sediment, P1, being 
the high removal percentages maintained over time. For the consortium derived from 
activated sludges, P2, Prx removal percentage was 59% after 2 weeks of experiment, 
increasing to 75% by the 6th week. In each sampling period (in weeks), differences between 
the two consortia were significant (p<0.05). 
Figure 17 - Removal percentage of Bzf in the consortia of isolates, over time. B1 – Estuarine 
Sediments, Static; B2 – Activated Sludge, Static; B3 - Activated Sludge, Agitation. a – 
different from other consortia at same period (p<0.05) 
Figure 18 - Removal percentage of Prx in the consortia of isolates, over time. P1 
– Estuarine Sediments, Static; P2 – Activated Sludge. Static. a - different between 
consortia at same period (p<0.05) 
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4.1.1. Fluoride Anion Release 
The results of defluorination obtained for medium inoculated with each of the two 
consortia produced with isolated strains previously exposed to Prx showed variations in the 
defluorination percentages over time (Fig. 19). The defluorination percentage increase over 
time until the 6th week. By this time defluorination percentage was significantly lower 
(p<0.05) for the consortium originated from activated sludge (P2) than for the consortium 
originated from estuarine environment (P1). 
 
Figure 19 - Percentage of defluorination in the consortia of isolates, over time, in Prx 
microcosms. P1 – Estuarine Sediments, Static; P2 – Activated Sludge. a – Different between 
consortia, at same period (p<0.05) 
 
4.2. DISCUSSION 
As mentioned, each microbial consortium exposed during several weeks to each 
pharmaceutical compound was cultivated in solid medium to differentiate bacterial strains 
present in each one of them. One should be aware that, nevertheless, several strains 
present in the initial consortia cannot be cultivable in solid medium (Hosokawa et al., 2009). 
Bacterial strains were grown in both media with and without the respective pharmaceutical 
compound. 
In this study, results indicated that the number of bacterial strains able to grow in a 
nutrients medium (PCA) was higher than the number of strains able to grow in a medium 
enriched with pharmaceuticals (MM-pharmaceutical). The presence of xenobiotics in the 
environment can affect microbial density (Oladele, 1999). Indeed, the xenobiotic presence 
at high concentrations can decrease the density of the sensitive species, while some 
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species can resist to its presence. In addition, these species can be able to degrade the 
xenobiotic. Resistant species have the capacity to produce biodegradative enzymes and 
use the excess of toxicant as nutrient source, being able to proliferate in the presence of 
the xenobiotic (Oladele, 1999). 
The obtained bacterial strains were combined, creating a new microbial consortium 
with an expected potential to degrade the respective pharmaceutical compound, Bzf or Prx. 
Each one of these new consortia was re-suspended in new MM doped with the respective 
pharmaceutical compound and compound degradation/removal was evaluated, in co-
metabolism with acetate.  
Results indicated that Bzf removal varied along time and with the microbial 
consortium. For consortia B1 and B2 mantained under static conditions, the highest Bzf 
removal percentages (>97%) were achieved by the end of week 4. However, by the end of 
week 2, Bzf removal percentage was higher for consortium B1, originated from estuarine 
sediment, than for consortium B2, originated from activated sludge. Discrepancy in the 
performance between these two consortia can be related with consortia acclimatization. 
Inoculation was performed with similar amounts of biomass, however, the equilibrium in 
consortia can occur in a different way, creating a lag time (Zhu et al., 2007, Yamamoto et 
al., 2009). Furthermore, the passing from a solid to a liquid medium can also influence 
acclimatization time (Wang et al., 2016).  
As for consortium B3, originated from activated sludge under agitation, results 
indicate that this consortium was not able to reach a high Bzf removal percentage, even 
decreasing after 6 weeks. The decrease in efficiency removal of Bzf observed for consortia 
B3 can be due to the incapability of the consortium to completely remove Bzf from solution. 
In fact, the overload of the pharmaceutical over feeding cycles may have generated toxicity 
to the species able to degrade the compound. In stress conditions, as exposure to 
pharmaceuticals, the microbial community must develop detoxication mechanisms to be 
able to proliferate (Dey et al., 2016). High concentration of toxicants can increase lag time, 
particularly if the number of microorganisms with degradation capability is low comparing to 
the amount of chemical compound in this medium (Wang et al., 2016). So, this consortium 
is probably not the most suitable one to degrade Bzf, indicating that the agitation conditions, 
in which the consortium was maintained, were effectively not the most appropriated ones. 
In fact, as verified at the previous experiment (Chapter 3), different incubation conditions 
induced differences between the two communities from the same source, in microcosms 
enrichment. That way, differences in removal of Bzf from consortia originated under different 
agitation conditions is not surprising.  
Regarding Prx removal, the two consortia had different origins (P1 from estuarine 
sediment and P2 from activated sludge), but were kept under the same static conditions. 
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For consortium P1 high removal percentages (> 90%) were observed already after 2 weeks 
of inoculation, being this removal percentage maintained over the following weeks. As for 
consortium P2, removal percentages only reached the maximum value after 6 weeks. 
However, this maximum was lower than the one observed for consortium P1. Release of 
fluoride anion results are in agreement with the results obtained for P2 consortia. This is, 
defluorination of Prx was proportional to removal rate at weeks 4 and 6, indicating that Prx 
was being effectively degraded into a non-fluorinated compound. For consortium P1, 
despite the immediately high Prx removal percentages, defluorination efficiency only 
reached the maximum value at 6th week, indicating that Prx degradation pathway over time 
differed among the consortia. One should be aware that as observed in the previous 
experiment, Prx can undergo abiotic degradation too. Nevertheless, fluoride anion 
concentration at week 6 was higher for consortium P1, originated from estuarine sediment 
indicating that this consortium was more effective in Prx degradation/removal. 
Bioremediation techniques require microbial consortia or microbial processes that make 
possible the decontamination of polluted sites (Juwarkar et al., 2010). Regarding the 
compounds in study, the key reaction during microbial degradation is dehalogenation, 
without forming intermediary products containing the halogen (Janssen et al., 2001). 
Dehalogenation consists in a substitution of the halogen component. In this way, the 
chemical compound can be easily degraded (Janssen et al., 2001). The increase in 
defluorination efficiency can be a response of the consortia to the presence of contaminant, 
since enzymes synthesis (or cessation) is controlled at molecular level, through the 
activation of specific genes (Oladele, 1999).  
Comparing results obtained at the present experiment with removal results obtained 
in the previous experiment (Chapter 3), it is possible to observe some differences in 
microcosms assembled with microorganisms from activated sludge. Indeed, consortia with 
microorganisms of activated sludge treated with Bzf that derived from agitation conditions 
(B3) had lower efficiency removals comparing with the observed in previous experiment, as 
well as for consortia derived from activated sludge treated with Prx (P2). Over time, removal 
efficiency did not achieve the values observed for the first experiment. However, in case of 
consortia exposed to Prx, defluorination efficiency achieved the maximum observed 
previously in the first experiment. Regarding consortia originated from the estuarine 
sediments, no differences were found in terms of pharmaceuticals removal with, in case of 
Prx, high defluorination rates, indicating the efficiency of this consortia to degrade Prx. 
Results obtained for both pharmaceutical compounds highlight that consortia 
obtained from estuarine sediment had a quicker acclimatization in microcosm, comparing 
to consortia from activated sludge. Moreover, at least for Prx, the consortium with bacterial 
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strains obtained from estuarine sediment seemed to be more effective for the compound 
degradation. 
WWTP were designed to remove organic matter from sewage generated in 
households and hospital effluents, being under specific operation and regulation (Halling-
Sørensen et al., 1998). Estuarine environments have a huge anthropogenic interest. The 
rapid urbanization and industries and shipping presence nearby, generated contamination 
through urban runoff and industrial effluents transport of chemicals (Sun et al., 2012). Thus, 
strains present in each consortia, may be different not only because of site characteristics 
but also due to the different previous exposition to chemicals at the source.  
 
4.3. CONCLUSIONS 
Results obtained indicated that isolated strains derived from enrichment culture from 
the previous experiment were able to degrade the studied pharmaceuticals, however 
different values of efficiency were observed. Consortia derived from estuarine sediment 
required less time of acclimation to the experimental conditions, since at the end of the 
second week, high removal efficiencies (>97%) were already observed. However, isolated 
strains from activated sludge showed to remove both pharmaceuticals, more efficiently in 
static conditions. Defluorination of Prx increased over time in both consortia exposed to this 
pharmaceutical, however the maximum value of defluorination was achieved only in isolated 
strains from estuarine sediment. Future identification of the different strains isolated from 
the different consortia is important information to understand which type of bacteria are 
involved in degradation process of the pharmaceuticals. This way, new knowledge will be 
provided about this subject. 
  
58 
 
 
 
 
 
 
 
 
 
 
CHAPTER 5 
CONCLUSIONS AND FUTURE PERSPECTIVES 
 
  
59 
 
5. CONCLUSIONS AND FUTURE PERSPECTIVES 
  The present work demonstrates the ability of autochthonous microorganisms from 
Douro estuary sediment and from activated sludge from a local WWTP to degrade Bzf or 
Prx in different experimental conditions (agitation vs. static). Although abiotic processes 
may lead to partial removal of Prx, dehalogenation only occurred in the presence of 
microorganisms, indicating the importance of their presence for the degradation of Prx. 
Regarding Bzf, removal was only due to the presence of microorganisms as abiotic 
degradation was not significant.  
The initial microbial community present in estuarine sediment had higher bacterial 
richness and diversity, comparing with that from the activated sludge. Important changes 
occurred in the microbial community structure, influenced by time of experiment, incubation 
conditions and pharmaceuticals presence. Indeed, incubation conditions affected not only 
the bacterial community structure, but also the efficiency of pharmaceuticals removal that 
was initially lower under agitation than under static conditions. Still, despite the alterations 
in community structure observed along the study, high efficiency of pharmaceuticals 
removal was obtained at the end of the experiment.  
Consortia of isolated strains derived from enrichment culture were able to degrade 
the studied pharmaceuticals, however different values of efficiency were observed. Higher 
efficiencies of pharmaceutical removal were observed in consortia originated from estuarine 
sediments. Regarding the consortia derived from activated sludge, pharmaceuticals 
removal was more efficiency under static than under agitation conditions. Defluorination of 
Prx increased over time in both consortia exposed to this pharmaceutical, however the 
maximum defluorination rate was achieve only in the consortium originated from estuarine 
sediments. 
Thus, these results demonstrate that autochthones microorganism communities 
from estuarine environment and associated WWTP, have the potential to be used in 
bioremediation techniques for the removal of pharmaceuticals under specific conditions. 
Identification of isolated strains will provide new knowledge about bacteria potentially 
involved in Prx and Bzf removal and degradation processes. 
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